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Background: Matrix metalloproteinases (MMPs) virtually degrade all components of the extracellular matrix and are mainly expressed in tissues
following inflammation or remodeling. Increased expression of certain MMPs in sputum and bronchoalveolar lavage of patients with cystic
fibrosis (CF) is related to impaired lung function. We investigated whether a panel of serum MMPs is associated with both, impairment of
pulmonary function and occurrence of pulmonary exacerbations (PEx) in adult patients with CF.
Methods: Serum concentrations of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, and TIMP-1 were determined by
ELISA in 54 adult CF patients. PEx was defined based on a score established by Rosenfeld in 2001. MMP-1, MMP-8, MMP-9 and TIMP-1 were
assessed in 7 CF patients with PEx before and after systemic antibiotic therapy.
Results: Of the 54 CF patients, PEx was diagnosed in 16 different CF patients. Compared to healthy controls, MMP-1, MMP-8, and MMP-9,
serum levels were elevated in CF patients and correlated with PEx. MMP-8 expression was associated with impaired lung function. For MMP-2,
we observed a decreased expression and an association of MMP-2 decline with PEx. Antibiotic treatment of CF patients with PEx led to a
decrease of MMP-1, MMP-8 and active MMP-9 protein concentration.
Conclusions: Increased serum expression of certain MMPs is associated with occurrence of PEx and impaired lung function in CF. Hence, these
MMPs might serve as surrogate markers for PEx.
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Cystic fibrosis (CF) is the most common genetic disease
in the Caucasian population affecting approximately 1 in 3200
newborn [1]. CF is a complex, hereditary medical disorder,
which is caused by a variety of mutations in a gene called cystic
fibrosis transmembrane conductance regulator. The subsequent
chloride channel defects result in intraluminal hydration defi-
ciency and mucus accumulation [2]. CF has a highly variable
genotype, phenotype, and clinical presentation. Predominantly
exocrine glands of the lungs, paranasal sinus, pancreas, and
intestine, as well as sweat ducts, bile ducts, and, in male indi-
viduals, spermatic ducts are affected. Due to earlier diagnosis
and improved supportive care thereafter the average survivald by Elsevier B.V. All rights reserved.
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However, a curative therapeutic approach is still not in sight, and
morbidity andmortality of the patients thus remain considerable.
Most of the morbidity and mortality in cystic fibrosis (CF)
results from its pulmonary manifestations. CF lung disease is
clinically characterized by episodic increases in respiratory symp-
toms, such as cough and sputumproduction, often accompanied by
systemic symptoms such as weight loss, anorexia, and fatigue [4].
These changes in pulmonary capability from the patient's baseline
necessitating treatment are termed pulmonary exacerbations [5].
Despite the central role that pulmonary exacerbations play in both,
bench and clinical research and bedside patient care, a standardized
definition has neither been published nor accepted yet. Thus, clas-
sification of clinical signs and symptoms with regard to pulmo-
nary exacerbation remains essentially a clinical diagnosis [6].
Cystic fibrosis lung disease is believed to be mediated by
neutrophil products, including proteases and oxidants [7]. One
of the hallmarks of CF and other chronic lung diseases such as
asthma, bronchiectasis, emphysema, chronic obstructive pul-
monary disease (COPD), and idiopathic pulmonary fibrosis is
the abnormal remodeling of tissue and in particular the accu-
mulation of extracellular matrix (ECM) [8–10].
Matrix metalloproteinases (MMPs) constitute a family of 24
mammalian extracellular or membrane-bound proteinases that
hold the ability to degrade all protein components of the ECM
[10]. The expression of several MMPs and their physiological
inhibitors, tissue inhibitors of metalloproteinases (TIMPs), is
crucial for physiological processes including development,
wound healing, and cell trafficking in the respiratory tract. The
majority of MMPs is only expressed in damaged tissues due to
inflammation or remodeling processes [10]. The dysregulation of
proteolytic MMP activity in these pathological states either leads
to exaggerated ECM turnover, impaired repair, and scar formation
or to ECM accumulation with subsequent tissue fibrosis [8–10].
Earlier studies have investigated sputum/bronchoalveolar
lavage fluid MMP levels in children and adults with CF. These
studies showed that MMP-9 and TIMP-1 are up-regulated in the
bronchial compartment and that this is inversely related to lung
function [7,11–13]. Up to now, it has not been investigated if
similar changes can be detected in blood samples of adult patients
with CF. Against this background, we thought to investigate
whether a panel of serumMMPs is associatedwith both, impaired
lung function and the occurrence of pulmonary exacerbations in
adult patients with CF. Considering the underlying pathophysiol-
ogy of the ECM we further hypothesized that some MMPs may
well serve as useful surrogate markers of pulmonary exacerbation
thereby facilitating diagnosis.
2. Patients and methods
2.1. Patient recruitment and assessment
All patients and controls were informed about the study and
gave their written informed consent. The study was approved by
the local ethics committee (AZ 70/07). From February 2006 to
March 2007 54 consecutive CF patients were enrolled for the
study. The diagnosis of CF had been established by sweat testand later confirmed by genetic tests in all subjects. About 70%
(37 out of 54) of our CF patient cohort carried the mutation
ΔF508. All patients were treated according to established
European and U.S. guidelines [14,15]. Patients were regularly
seen in the CF outpatient clinic every 3 months, and at each visit
the following parameters were routinely assessed: patient
history/physical examination, sputum and blood samples, and
pulmonary function tests including blood gas analysis (BGA).
Serum samples from all patients were taken during the office
hours of the CF outpatient clinic from 8 AM to 14 PM for the
immediate determination of CRP, leukocytes, differential white
blood cell count and procalcitonin (PCT). PCT was measured
using the BRAHMS PCTsensitive kryptor immunofluorescence
assay (Brahms AG, Henningsdorf, Germany). Serum was
centrifuged and stored at −80 °C for later analysis of MMPs.
Pulmonary function tests were carried out using body plethys-
mography according to established guidelines [16] on a
MasterScreen V4.6 (VIASYS Healthcare GmbH, Hoechberg,
Germany). All values were normalized to weight adapted normal
values with respect to the individual body-mass-index (BMI). A
capillary blood sample was procured for BGA with a glass
capillary from the tip of the ear after induction of hyperaemia
(Finalgon®, Boehringer Ingelheim Pharma GmbH, Germany).
BGAs were immediately processed on an AVL-OMNI-Modular
System analyzer (Roche Diagnostics, Penzberg, Germany).
Patients were instructed to report to the clinic immediately
whenever symptoms suggestive of acute pulmonary exacerba-
tion (PEx) appeared. PEx was defined based on the PEx score
established by Rosenfeld in 2001 [17]. The PEx score consists
of six common clinical findings each weighted by a certain
coefficient (in brackets): decreased exercise tolerance (1.8),
increased cough (1.5), increased cough/sputum congestion
(1.5), school or work absenteeism (1.6), increased adventitial
sound on lung examination (1.2), and decreased appetite (1.1)
[17]. Pulmonary exacerbation was presumed when the PEx
score exceeded the critical value of 2.6. If senior CF specialists
considered the exacerbation severe enough systemic antibiotic
therapy was instituted. Choice of antibiotic therapy was based
on the results of the most recent sputum culture. The following
classes of antibiotics were used: (i) gyrase inhibitors (6 of 16
PEx) (ii) carbapenems plus aminoglycosides (3 of 16 PEx) (iii)
acylaminopenicillins plus ß-lactamase inhibitors (2 of 16 PEx)
(iv) acylaminopenicillins plus ß-lactamase inhibitors plus
aminoglycosides (5 of 16 PEx).
Serum from 40 apparently healthy individuals was collected
by the local transfusion services and assayed serving as MMP
control. None of the volunteers had a history of asthma or
clinical signs or symptoms of respiratory distress or infection at
the time of blood sampling. All volunteers were non-smokers.
The local transfusion service was provided a list with age, sex
and BMI of all CF patients. Suitable donors were then selected
according the matching criteria from transfusion services' staff.
2.2. Expression analysis of MMP and TIMP-1
Serum MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-
9, MMP-12, and MMP-13 protein levels were measured using a
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detection of human MMPs, according to the manufacturer's
instructions (Fluorokine MAP multiplex human MMP panel,
R&D-Systems, Wiesbaden, Germany). Serum was prediluted
1:4 for measurement of MMP-7, MMP-12, and MMP-13 and
1:50 for MMP-1, MMP-2, MMP-3, MMP-8 and MMP-9,
respectively. Multiplex ELISA of all samples (as depicted in
Fig. 1) was performed twice on a Luminex 100 reader (Luminex
cooperation, Austin, USA). TIMP-1 concentration of all serum
samples was quantified in 1:100 prediluted serum using a
commercially available Kit (human TIMP-1 Quantikine ELISA
Kit, R&D-Systems, Wiesbaden, Germany). MMP-1, MMP-8,
total and active MMP-9 protein concentration in seven patients
with PEx before and after the administration of a systemic
antibiotic therapy (as depicted in Fig. 2) were assessed in 1:50
(MMP-1, MMP-8) and 1:100 (total and active MMP-9)
prediluted serum using commercially available kits (MMP-1:
human Pro-MMP-1 ELISA Kit, MMP-8: human total MMP-8
Quantikine ELISA Kit, total MMP-9: human total MMP-9 duo
set, active MMP-9: Fluorokine Quantitec Kit, all R&D-
Systems, Wiesbaden, Germany). Assays before and after
administration of systemic antibiosis were performed twice on
an Infinite200 microplate reader for MMP-9 activity (Tecan,
Crailshaim, Germany) and on a fusion universal microplate
analyzer (Perkin Elmer, Waltham, USA) for MMP-1, MMP-8,
total MMP-9 and TIMP-1 protein concentration.
2.3. Statistical analysis
Prior to more sophisticated statistical calculations, normal
distribution of the data was tested using the Kolmogorov–
Smirnov test and visualization of histograms. Failing to meet
criteria for normal distribution all data were analysed using non-
parametric tests (Mann–Whitney U test for unpaired samples,
Wilcoxon matched-pairs signed-rank test for paired samples,
and Spearman's rank correlation). Regression analysis was
adjusted for multiple testing using the method of Bonferroni.
Unpaired data are presented as median and interquartile range
with 95% confidence interval. Values deviating from the box byFig. 1. a. Serum MMP-1 (A), MMP-2 (B), MMP-3 (C), MMP-7 (D), MMP-8 (E)
pulmonary exacerbation (CF-no PEx, n=38), and CF patients suffering from pulmon
ELISA. Significant differences are pointed out (⁎Pb0.05, ⁎⁎Pb0.01). Compared
without PEx (2.2-fold, Pb0.001) and further progression in those with PEx (3.8-fold
patients with PEx than in those without PEx (1.7-fold, Pb0.001). MMP-1 was eleva
and healthy subjects (2.5-fold, P=0.021). Compared to healthy controls, MMP-2 sho
Pb0.001) to those with PEx (−1.7-fold, Pb0.001). Patients with PEx revealed signi
P=0.015). Data are presented in box-and-whisker-plots. Values deviating from the bo
(Δ) with a distance of more than 3 box-lengths were not considered for statistical anal
(C), and the MMP-9/TIMP-1-ratio (D) in healthy control subjects (n=40), CF patients
from pulmonary exacerbation (CF-PEx, n=16). Protein assay was performed by mul
Compared with healthy subjects, total and activeMMP-9 showed enhanced protein lev
7.9-fold, Pb0.001) and further progression in those with PEx (total MMP-9: 2.3-fold
patients with PEx compared to those without PEx (1.1-fold, P=0.013) and healt
increased in both, patients with (2-fold, P=0.001) and without (1.5-fold, P=0.001) p
and-whisker-plots. Values deviating from the box by 1.5- to 3-fold interquartile range
box-lengths were not considered for statistical analysis.1.5- to 3-fold interquartile range were defined as outliers.
Extreme values with a distance of more than 3 box-lengths were
not considered for statistical analysis. P values shown for
regression analysis include Bonferroni's correction for multiple
testing, P valuesb0.05 were considered statistically significant.
Statistical analysis was performed using SPSS version 12.0
(SPSS Inc., IL, USA).
3. Results
3.1. Patient characteristics
Demographic data of the 54 CF patients and 40 volunteers
are depicted in Table 1a. The volunteers without lung disease
serving as a control group were matched with the CF patients
with regard to anthropometric parameters (age, sex, and BMI).
3.2. Lung function and clinical chemistry
During the study period, PEx was diagnosed in 16 different
CF patients with a mean Rosenfeld score of 4.8 (median 5.6,
interquartile range 3.0) (Table 1b). Lung function was
significantly impaired in PEx patients compared to CF patients
without clinical signs of exacerbation whereas blood gases were
similar in both groups (Table 1b). Considering laboratory values
that usually represent inflammation or infection—e.g. CRP,
leukocytes, neutrophils—significant differences were also
observed (Table 1b).
Procalcitonin (PCT), usually regarded the most reliable
parameter to rule out bacterial infection (negative predictive
value 95%, positive predictive value 89%, [18]) did not dis-
criminate between those patients who fulfilled clinical criteria of
PEx and those who did not.
3.3. MMP serum levels
Compared with healthy subjects, in CF patients without PEx
serum protein levels of MMP-8, MMP-9, and MMP-9 activity
were increased whereas MMP-2 protein levels declinedprotein concentrations in healthy control subjects (n=40), CF patients without
ary exacerbation (CF-PEx, n=16). Protein assay was performed by multi analyte
with healthy subjects, MMP-8 showed enhanced protein levels in CF patients
, Pb0.001). Moreover, MMP-8 protein was significantly expressed higher in CF
ted in CF patients with PEx compared to those without PEx (2.2-fold, P=0.014)
wed progressive decreased expression from CF patients without PEx (−1.4-fold,
ficantly reduced MMP-2 expression compared to those without PEx (−1.2-fold,
x by 1.5- to 3-fold interquartile range were defined as outliers (o). Extreme values
ysis. b. Serum protein concentrations of total (A) and active (B) MMP-9, TIMP-1
without pulmonary exacerbation (CF-no PEx, n=38), and CF patients suffering
ti analyte ELISA. Significant differences are pointed out (⁎Pb0.05, ⁎⁎Pb0.01).
els in CF patients without PEx (total MMP-9: 1.4-fold, Pb0.001; activeMMP-9:
, Pb0.001, MMP-9 activity: 10.3-fold, Pb0.001). TIMP-1 was enhanced in CF
hy controls (1.1-fold, P=0.007). The MMP-9/TIMP-1-ratio was significantly
ulmonary exacerbation compared to healthy controls. Data are presented in box-
were defined as outliers (o). Extreme values (Δ) with a distance of more than 3
Fig. 2. Serum levels of MMP-1 (A), MMP-8 (B), total (C) and active MMP-9 (D), TIMP-1 (E) protein and the MMP-9/TIMP-1 ratio (F) in CF patients with pulmonary
exacerbation before and after initiation of antimicrobial therapy. Antibiotic treatment led to a significant decline of serum MMP-8 (P=0.028), active MMP-9
(P=0.028) and MMP-1 protein concentration (P=0.018). Reduction of total MMP-9, TIMP-1 and of the MMP-9/TIMP-1 ratio did not reach the level of statistical
significance (MMP-9: P=0.176, TIMP-1: P=0.063, MMP-9/TIMP-1 ratio: P=0.237). Data are presented in box-and-whisker-plots. Values deviating from the box by
1.5- to 3-fold interquartile range were defined as outliers (o). Extreme values (Δ) with a distance of more than 3 box-lengths were not considered for statistical analysis.
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16.53 ng/ml; MMP-9: no PEx: 485.71 ng/ml and healthy:
345.99 ng/ml; MMP-9 activity: no PEx: 594 ng/ml and healthy:
75 mg/ml; MMP-2: no PEx: 201.7 ng/ml and healthy: 279.82 ng/
ml, Fig. 1a and b). These differences were even more pronounced
when healthy controls were compared with the PEx population
(MMP-2: PEx: 168.44 ng/ml; MMP-8: PEx: 62.12 ng/ml; MMP-9: PEx: 792.45 ng/ml; MMP-9 activity: PEx: 770.5 ng/ml, Fig. 1a
and b). MMP-1 and TIMP-1 were increased in CF patients with
PEX compared to healthy controls and CF patients without PEx
(MMP-1: PEx: 11.11 ng/ml, no PEx: 5.02 ng/ml, healthy:
4.53 ng/ml; TIMP-1: PEx: 280.75 ng/ml, no PEx: 248.82 ng/ml,
healthy: 251.79 ng/ml). Compared with healthy controls the
MMP-9/TIMP-1 ratio was significantly increased in both
Table 1a
Demographic data of healthy controls (n=40) and CF patients (n=54).
Healthy
controls
CF patients
Age (years)
Mean±SD 26.8±5.65 31.6±6.86
Median 26.5 32.3
25th/75th percentile 22/31.5 25.9/36.2
Sex (male/female) 20/20 25/29
Body-mass-index [kg/m2]
Mean±SD a 21.44±3.17
Number of patients with long-term medication
Antibiotics 0 45
Anti-inflammtory drugs 0 48
a The local transfusion service was provided a list with age, sex and BMI of all
CF patients. Suitable donors were then selected according the matching criteria
from transfusion services' staff.
Table 1b
Demographic and clinical data of CF patients with pulmonary exacerbation (CF-
PEx, n=16) compared to those without PEx (CF-no PEx, n=38). a
CF-no PEx CF-PEx
Age (years)
Mean±SD 31.9±7.3 30.9±5.8
Median 32.4 32.2
25th/75th percentile 25.6/37.2 26.1/35.1
Sex (male/female) 22/16 6/10
%VCb 77.69±16.66 56.55±14.5⁎⁎
%FEV1b 63.76±21.97 40.28±14.39⁎⁎
%MEFb 29.14±22.37 14.79±10.27⁎
pO2 (mm Hg) 76.58±9.17 70.79±11.46
pCO2 (mm Hg) 37.64±3.87 38.79±9.83
[Ref c] CF-no PEx CF-PEx
Rosenfeld score 0.47±0.68 4.76±1.62 ⁎⁎
CRP (mg/l) [b1] 6.20±5.62 38.96±40.61 ⁎⁎
Procalcitonin (ng/ml) [b0.1] 0.046±0.023 0.042±0.024
Leukocytes d [4–11] 7.37±2.23 10.14±4.13 ⁎
Neutrophils d [1.8–7.7] 5.05±2.0 8.04±3.9 ⁎⁎
Eosinophils d [0.0–0.5] 0.14±0.1 0.16±0.15
Basophils d [0.0–0.2] 0.025±0.028 0.029±0.026
Monocytes d [0.0–0.8] 0.54±0.21 0.74±0.35⁎
Lymphocytes d [1.0–4.8] 1.42±0.57 1.69±0.45
a All data are given as mean±SD.
b Lung function values are given as percentages and were normalized to
weight adapted normal values (=100%) with respect to the individual body-
mass-index (BMI).
c Reference values from directory of services, institute of clinical chemistry,
university hospital, Gießen.
d Cell counts (109/l).
⁎ Significantly different, Pb0.05.
⁎⁎ Significantly different, Pb0.01.
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healthy: 1.39, Fig. 1b). MMP-7 and MMP-3 did not differ
between healthy controls and CF patients with or without PEx
(MMP-3: PEx: 11.23 ng/ml, no PEx: 11.93 ng/ml, healthy:
10.63 ng/ml; MMP-7: PEx: 1.27 ng/ml, no PEx: 1.26 ng/ml,
healthy: 1.52 ng/ml).
Within the 54 CF patients, an inverse relationship between %
FEV1 and %VC and MMP-8 (r=−0.468, Pb0.001 and r=
−0.499, Pb0.001) was detected (Table 2). Albeit statistically
significant, the coefficient of determination (r2), revealed a
weak association only. Subgroup analyses of patients with PEx
and those without PEx revealed no significant association
between MMP-8 expression and lung function parameters.
Correlations between MMP-1, MMP-2, MMP-3, MMP-7,
MMP-9, MMP-9 activity, TIMP-1, the MMP-9/TIMP-1 ratio
and %FEV1 and %VC did not reach the level of statistical
significance (Table 2).
3.4. Effects of antibiotic and anti-inflammatory therapy
On the basis of the Rosenfeld score, PEx was diagnosed in
16 distinct CF patients. However, determination of MMP-1,
MMP-8, total and active MMP-9, and TIMP-1 before and after
initiation of antibiotic therapy (on average 35 days after
initiation, range from 21 to 68 days) was only possible in
seven patients with PEx. The other 9 patients with PEx received
orally administered systemic antibiotics in our CF outpatient
clinic. Unfortunately the close follow-up of these patients with
control of clinical and serological response to antibiotic therapy
was carried out by a pneumologist in a private practice. We
therefore did not obtain serum samples after completion of
antibiotic therapy. Thus of the 16 patients with PEx nine were
lost to follow-up. In the remaining seven patients, median levels
of MMP-8, active MMP-9 and MMP-1 protein were signifi-
cantly decreased in samples obtained after antibiotic treatment
compared with those collected prior to the therapeutic
intervention (MMP-1: 9.82 ng/ml vs. 7.62 ng/ml, P=0.018;
MMP-8: 92.49 ng/ml vs. 67.92 ng/ml, P=0.028; active MMP-
9: 902 ng/ml vs. 855 ng/ml, P=0.028, Fig. 2). Reduction oftotal MMP-9, TIMP-1 and the MMP-9/TIMP-1 ratio after
systemic antibiosis did not reach the level of statistical
significance (total MMP-9: 1612.88 ng/ml vs. 1617.84 ng/ml,
P=0.176; TIMP-1: 306.72 ng/ml vs. 274.12 ng/ml, P=0.063;
MMP-9/TIMP-1 ratio: 7.44 vs. 5.47, P=0.237). Antibiotic
treatment led to significant decline of the Rosenfeld score from
5.63 to 1.74. Neither lung function nor standard laboratory
parameters of infection (i.e. CRP, PCT, white blood cell counts)
were significantly changed after antibiotic therapy for pulmon-
ary exacerbation (Table 3).
Baseline macrolide therapy, long-term antibiotic or anti-
inflammatory therapy did not change MMP- or TIMP-1 ex-
pression in the CF population. Original data are provided as
Supplementary material.
3.5. Correlation between serum MMP and TIMP-1 levels and
inflammatory cell counts in blood
Total white blood cell counts correlated to circulatingMMP-1,
MMP-8, total and active MMP-9, and TIMP-1 (Table 4).
Differential blood count revealed associations of neutrophils
with the expression ofMMP-1, MMP-8, total and activeMMP-9.
MMP-8 and MMP-9 were furthermore correlated with monocyte
counts (Table 4). Considering correlation coefficients exceeding
Table 2
Correlation between parameters of lung function and serum MMP- and TIMP-levels.
CF-patients
CF-total (n=54) CF-no PEx (n=38) CF-PEx (n=16)
%VC a %FEV1 a %VC a %FEV1 a %VC a %FEV1 a
MMP-1 r=−0.406 r=−0.339 r=−0.277 r=−0.182 r=−0.512 r=−0.418
PN0.1 PN0.1 PN0.1 PN0.1 PN0.1 PN0.1
MMP-2 r=0.065 r=0.103 r=−0.106 r=0.031 r=0.046 r=−0.262
PN0.1 PN0.1 PN0.1 PN0.1 PN0.1 PN0.1
MMP-3 r=0.044 r=−0.061 r=0.069 r=−0.048 r=0.209 r=−0.200
PN0.1 PN0.1 PN0.1 PN0.1 PN0.1 PN0.1
MMP-7 r=−0.273 r=−0.175 r=−0.277 r=−0.180 r=−0.266 r=−0.185
PN0.1 PN0.1 PN0.1 PN0.1 PN0.1 PN0.1
MMP-8 r=−0.499 r=−0.468 r=−0.474 r=−0.379 r=−0.060 r=−0.111
Pb0.001 ⁎⁎ Pb0.001 ⁎⁎ P=0.084 PN0.1 PN0.1 PN0.1
MMP-9 r=−0.257 r=−0.298 r=−0.255 r=−0.232 r=0.196 r=−0.144
PN0.1 PN0.1 PN0.1 PN0.1 PN0.1 PN0.1
MMP-9 activity r=−0.291 r=−0.299 r=−0.318 r=−0.252 r=0.455 r=0.153
PN0.1 PN0.1 PN0.1 PN0.1 PN0.1 PN0.1
TIMP-1 r=−0.290 r=−0.251 r=−0.114 r=−0.101 r=−0.152 r=−0.197
PN0.1 PN0.1 PN0.1 PN0.1 PN0.1 PN0.1
MMP-9/TIMP-1 ratio r=−0.181 r=−0.222 r=−0.249 r=−0.231 r=0.437 r−=0.021
PN0.1 PN0.1 PN0.1 PN0.1 PN0.1 PN0.1
a Lung function values are given as percentages and were normalized to weight adapted normal values (=100%) with respect to the individual body-mass-index
(BMI).
⁎ Significantly different, Pb0.05.
⁎⁎ Significantly different, Pb0.01.
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MMP-9 revealed a clinically relevant association with both,
leukocyte and neutrophil counts.Table 3
Lung function and clinical data in CF patients with PEx (n=7) before and after
antibiosis (AB). a
CF before AB CF after AB P-value
%VC b 53.81±12.69 62.41±17.39 N0.1
%FEV1 b 39.8±11.03 50.1±16.1 0.090
%MEF b 13.7±5.3 17.99±12.1 N0.1
pO2 (mm Hg) 68.6±9.2 75.2±8.05 0.018 ⁎
pCO2 (mm Hg) 40.3±5.6 43.9±13.4 N0.1
[Ref c] CF before AB CF after AB P-value
Rosenfeld Score 5.63±1.35 1.74±1.08 0.028 ⁎
CRP (mg/l) [b1] 44.1±36.5 19.7±15.6 0.063
Procalcitonin
(ng/ml)
[b0.1] 0.058±0.037 0.034±0.023 0.063
Leukocytes d [4–11] 11.6±1.5 10.8±1.2 N0.1
Neutrophils d [1.8–7.7] 7.2±0.9 8.3±2.1 N0.1
Eosinophils d [0.0–0.5] 0.18±0.04 0.3±0.05⁎ 0.028 ⁎
Basophils d [0.0–0.2] 0.027±0.007 0.027±0.011 N0.1
Monocytes d [0.0–0.8] 0.98±0.12 0.7±0.1 0.075
Lymphocytes d [1.0–4.8] 2.2±0.27 2.04±0.15 N0.1
a All data are given as mean±SD.
b Lung function values are given as percentages and were normalized to
weight adapted normal values (=100%) with respect to the individual body-
mass-index (BMI).
c Reference values from directory of services, institute of clinical chemistry,
University hospital, Gießen.
d Cell counts (109/l).
⁎ Significant difference between CF patients before and after the
administration of a systemic antibiotic therapy, Pb0.05.Neither MMP-12 nor MMP-13 was detected in serum of CF
patients or controls (concentration was below detection limit).
4. Discussion
Given the importance of pulmonary exacerbations in CF
with regard to patients' outcomes, remarkably little is known
about the underlying pathophysiology, and diagnosis remains
vague. Although the underlying precise cellular and molecular
mechanisms remain to be elucidated [19,20], it is commonly
accepted that pulmonary exacerbations are the result of an
increased bacterial endobronchial burden and the associated
inflammatory host response. Presumably this process is
associated with complex interactions between respiratory
epithelia, immune cells, and bacteria. Only recently pulmonary
exacerbation in patients chronically infected with Pseudomo-
nas aeruginosa have been attributed to the clonal expansion of
strains of microorganisms present at the patient's stable baseline
rather than to the acquisition of new strains [21].
Facilitating early and goal-directed therapy of pulmonary
exacerbation a robust diagnosis needs to be accomplished in
affected individuals. Unfortunately, until now neither a
standardized definition has been published nor accepted. As a
result the presence of an exacerbation remains essentially a
clinical diagnosis [6]. Three groups have systematically
evaluated the constellation of signs and symptoms that best
characterize a pulmonary exacerbation [17,22,23]. The results
of these three studies in different patient populations actually
demonstrated fairly good concordance. Of note, all scores
utilizing clinical signs and symptoms were more predictive
regarding pulmonary exacerbation than any laboratory data.
Table 4
Correlations between serum MMP and TIMP-1 levels and inflammatory
cell counts.
⁎Significantly different, Pb0.05.
⁎⁎Significantly different, Pb0.01.
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higher median serum levels of certain MMPs when compared to
healthy controls without lung disease and that this was inversely
related to lung function. Thus, the changes of MMPs occurring
in the bronchial tree of individuals with CF [7,11–13] seem to
be reflected in the blood compartment.
In serum of adult CF patients we found increased MMP-8
and MMP-9 expression. This rise in proteolytic enzyme activity
was associated with clinical signs suggestive for PEx. MMP-8
expression was furthermore associated with worsened lung
function tests. Indeed patients with PEx (classified by Rosenfeld
score) revealed significantly increased MMP expression levels
compared to those without PEx. The significant decrease of
activeMMP-9 serum levels after systemic antibiotic treatment in
seven patients with PEx emphasizes the etiologic link between
MMP expression and the occurrence of PEx. Besides CF other
chronic diseases reveal enhanced systemic levels of MMPs and
increased local MMP concentration: in COPD locally enhanced
MMP-9 levels as well as systemic MMP-9 increases have been
reported recently, and serum CRP and MMP-9 levels were
related to FEV1 decline. Both markers served as good can-
didates predicting a rapid decline of FEV1 in COPD patients
[24]. Moreover, higher MMP-9 serum concentration may be
related to increased airway obstruction and disease progression
[25]. However, we did not perform immunohistochemical
analyses to track down the MMP-secretion to a certain cir-
culating cell type. Thus, whether the MMP-9 activity reported
herein represents a simple “leak” from the inflammatory space
of the lung or does indeed represent a systemic inflammation
with potential systemic effects remains unclear. From our point
of view none of the hypothesis can be excluded right now.
Nevertheless, since we were able to demonstrate a correla-
tion between serum MMP-8 and MMP-9/active MMP-9 levels,
and leukocyte and neutrophil counts, it is likely that MMP
overexpression in CF is mainly induced by these inflammatory
cells. Considering our data, especially MMP-8 and MMP-9
might well serve as surrogate parameters for the occurrence of
PEx in patients with CF.Recent studies serve to emphasize the etiologic role of
MMP-8 and MMP-9 for pulmonary inflammation in CF
[26,27]: Perez and coworkers demonstrated the inhibition of
the inflammatory response in CF by peroxisome proliferator-
activated receptor (PPARγ) agonists, at least in part by the
attenuation of NFκB-driven processes such as MMP-9 produc-
tion [26]. Gaggar et al. found that MMP-8 and MMP-9 are
involved in the production of the peptide proline–glycine–
proline (PGP), which acts as a strong ECM-derived neutrophil
chemoattractant, and therefore may contribute to neutrophil
influx and airway damage in CF patients [27]. The authors
conclude that MMP inhibition may therefore be beneficial in
treating CF lung disease.
TIMP-1, among the most important inhibitors of MMP-9,
was significantly up-regulated in CF patients with PEx
compared to both, healthy controls and CF patients without
PEx. Pulmonary TIMP-1 expression is linked to a variety of cell
types including fibroblasts, alveolar epithelial cells, smooth
muscle cells and inflammatory cells such as neutrophils and
alveolar macrophages [28–30]. We observed a positive
association between increased TIMP-1 expression and leuko-
cyte counts. Interestingly, the rising MMP expression by far
exceeded the increase of TIMP-1. Consequently, it is unlikely
that TIMP-1 completely inhibits the increased MMP activity in
CF patients with PEx. It may well be that the observed TIMP-1
slope mainly reflects its acute-phase protein properties [31].
Thus, TIMP-1 is conjoined to the inflammatory response in PEx
rather than bound to structural matrix deposition eventually
leading to pulmonary fibrosis.
We observed a significant increase of serum MMP-1 con-
centration in CF patients with PEx. Furthermore, our studies on
the effect of systemic antimicrobial therapy in seven patients with
PEx revealed a significant decline in MMP-1 protein concentra-
tion after antibiosis. D'Armiento and coworkers were among the
first to describe the link between collagenase expression and lung
disease: in the lungs of transgenicmiceMMP-1 expression caused
pulmonary emphysema with disruption of the alveolar walls and
subsequent coalescence [32]. In contrast, Dunsmore et al. did not
detect any MMP-1 in lung epithelium of CF patients applying
immunostaining [33]. However, in our cohort of adult CF patients
we can neither ascribe the measured serum MMP-1 exclusively
to the lung epithelium, nor exclude other tissues or cell types as
relevant MMP-1 sources.
To the best of our knowledge, this study is the first to
demonstrate a significant decrease of MMP-2 serum levels in
CF patients compared with healthy controls. MMP-2 has been
measured in bronchoalveolar lavage (BAL) fluid of patients
with ALI, ARDS and COPD [34,35]. The main source of MMP-
2 in the lung is the endothelium where Gelatinase A (MMP-2) is
constitutively expressed. In contrast, bronchial epithelial cells,
alveolar type II cells, smooth muscle cells, and fibrocytes are
known to produce MMP-9 during infections and inflammatory
lung diseases. Infiltrating leukocytes, however, are thought to
be the major source of MMP-9 during inflammation [36].
Therefore, an excess of MMP-9 is associated with a pro-
inflammatory state, whereas MMP-2 can exert anti-inflamma-
tory effects by degrading the pro-inflammatory molecule
346 M. Roderfeld et al. / Journal of Cystic Fibrosis 8 (2009) 338–347monocyte chemoattractant protein (MCP)-3 into a CC-chemo-
kine antagonist which helps in the dampening of inflammatory
processes [37]. The difference in expression profile between the
two enzymes likely arises from a structural difference in the
promoter region of the respective genes. The promoter region
for the MMP-9 gene contains binding sites for the transcription
factor activator protein (AP)-1 [38]. Activation of the AP-1
transcription factor under pro-inflammatory conditions is likely
to account for the increased expression of MMP-9 during
inflammation. In contrast, the gene for MMP-2 lacks binding
sites for pro-inflammatory transcription factors such as AP-1
and, as a result, most pro-inflammatory stimuli fail to increase
MMP-2 transcription [39].
One might therefore speculate that decreased expression of
MMP-2 in patients with CF and further decline corresponding
with the occurrence of PEx may result from a unique regulation
pattern of this enzyme, i.e. a constitutive expression in lung
endothelium which is altered during inflammatory states.
In conclusion, increased serum protease activity is associated
with PEx in adult patients with CF. Especially MMP-8 and
MMP-9 might serve as reliable and easy to assess surrogate
markers of PEx. Whether goal-oriented inhibition of certain
MMP holds the potential to affect CF associated respiratory
tissue destruction thereby improving surrogate parameters of
lung function remains unclear.
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